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Prostate specific G protein coupled
receptor is associated with prostate cancer
prognosis and affects cancer cell
proliferation and invasion
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Abstract
Background: There is limited information about the clinical and biological significance of prostate specific G
protein coupled receptor (PSGR) in prostate cancer (PCa) initiation and progression. Here, we evaluated the
expression of PSGR protein, studied its diagnostic and prognostic value in PCa, and also explored its role in cancer
cell growth and invasion.
Methods: The expression of PSGR in paired adjacent normal prostate, high grade prostatic intraepithelial neoplasia
(PIN), and PCa were determined by immunohistochemistry on tissue microarrays constructed from 150 radical
prostatectomy specimens. The effects of PSGR on PCa cell growth and invasion were investigated using human PCa
cell lines.
Results: Membranous and cytoplasmic PSGR staining was observed at luminal epithelial cells of prostate. PSGR
protein expression was significantly higher in PIN compared to normal prostate. Interestingly, the expression of
PSGR decreased as PIN progressed to PCa. Low PSGR expression in PCa was associated with high Gleason score,
and poor overall survival. Activated PSGR increased cancer cell invasive ability, but retarded cell growth. PSGR did
not affect mTOR activity, but suppressed P70 S6 kinase activity.
Conclusions: PSGR may participate in PCa progression through affecting cell proliferation and invasion. High
expression of PSGR in PIN may implicate its role in early neoplastic transformation of PCa. Low expression of PSGR
in PCa may serve as a potential indicator for poor prognosis.
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Background
Prostate cancer (PCa) is the most common neoplasia
and the second leading cause of death from cancer in
American men [1]. To further improve patient outcome,
more efforts are needed to study the molecular mecha-
nisms underlying PCa development and progression.
Identification of new molecular markers for PCa would
allow more reliable diagnosis and prognosis, and provide
potential targets for optimizing therapeutic strategies.
Prostate Specific G protein Coupled Receptor (PSGR)
is a G protein coupled receptor that has been found to
have restricted expression in human prostate tissues by
Northern blot and real-time PCR analysis of over 50 dif-
ferent human tissue types [2]. The mRNA level of PSGR
increases significantly in the epithelial cells of prostate
intraepithelial neoplasia (PIN) and PCa compared to
non-cancerous controls and benign prostatic hyperplasia
(BPH), suggesting that PSGR may play important roles
in prostate cancer development and progression [2–4].
A high mRNA level of PSGR seems to correlate with
prostate specific antigen (PSA) level [5] but not with pa-
tient age, tumor stage, Gleason score, lymphovascular
invasion, or recurrence [3, 5, 6]. PSGR transcripts in
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urine may be used as an early diagnostic marker for PCa
[7]. A previous study with a panel of PSA, prostate
cancer gene 3 (PCA3), PSGR and α-methylacyl-CoA
racemase (AMACR) indicated that PSGR transcript
could increase the diagnostic specificity [6].
Recently, Neuhaus et al. reported that β-ionone, a
specific agonist of PSGR, could increase intracellular
Ca2+ flux [8]. They found that endogenous Ca2+-selective
transient receptor potential vanilloid type 6 (TRPV6)
channels were downstream molecules to mediate the
signaling from activated PSGR, which was dependent on
Src kinase activity [9]. Moreover, their data showed that
activated PSGR inhibited proliferation of LNCaP cells by
increasing apoptosis through MAPK signaling [8].
Notably, a recent study from Sanz et al. [10] reported that
activation of PSGR with β-ionone promoted migration
and invasion of LNCaP cells, as well as metastasis in
animal experiments.
These findings give rise to the possibility of using
PSGR as a marker for early diagnosis and prognosis, and
suggest a novel potential target for PCa treatment [4].
However, the endogenous ligands, biological, and patho-
logical significance of PSGR in the prostate remain un-
identified. To date, there has been little evaluation of
PSGR protein expression in normal prostate and PCa.
Therefore in this study, using immunohistochemistry,
we evaluated PSGR protein expression in various normal
human tissues, several PCa cell lines, and a cohort of
150 PCa specimens. We further studied the associations
of PSGR protein expression in PCa with related clinical
parameters and patient overall survival (OS). In addition,
we tested how activated PSGR affected PCa cell prolifer-
ation and invasion.
Methods
Patients’ recruitment and tissue samples
The pathology database at the University of Rochester
Medical Center (URMC) from 2004 to 2005 was searched
for radical prostatectomy and prostatic adenocarcinoma.
150 cases were identified and retrieved for histologic
review. The diagnosis of prostatic adenocarcinoma for
each case was confirmed by one of the two pathologists
(FL and WQC). Clinical and pathological information
including age, stage, Gleason score, lymphovascular inva-
sion, extraprostatic extension, and survival were collected
from the clinical notes and pathology reports. Human
tissue specimens obtained and processed at URMC were
collected under the protocol “Studies of biomarker ex-
pression in human tumors” (RSRB00020130) approved by
the University of Rochester Research Subjects Review
Board (RSRB). The institutional review board RSRB ap-
proved this retrospective study and waived the need for
consent. Patient records/information was anonymized and
de-identified prior to analysis.
Tissue microarrays
Archival, formalin-fixed, paraffin-embedded tissue blocks
from the selected patients were procured from the
Department of Pathology and Laboratory Medicine at
URMC. Tissue microarrays (TMAs) were constructed
from the selected paraffin blocks of 150 cases. For each
case, areas containing benign prostatic tissue, high grade
prostatic intraepithelial neoplasia, or prostatic adenocar-
cinoma were first marked by a pathologist for sampling.
Two 3 mm core samples were then retrieved from each
selected area in the donor paraffin blocks, and transferred
to a TMA paraffin block. Six cores were taken from each
individual case. A TMA grid map was made to keep track
of cores from the same prostatectomy specimen. The
Gleason grade for each PCa core was the same as that in
the final pathology report. Many tissue cores contained
two of the three tissue types (normal and PIN, PIN
and PCa). Each TMA block also included tissue cores
(normal liver, placenta, thyroid tissue, or small bowel)
as controls.
Reagents
α-ionone and β-ionone were purchased from Sigma
(St Louis, MO or NU-chek prep, INC. Elysian, MO),
dissolved in DMSO and stored at −80 °C. Specific anti-
bodies against AR, PSGR, Phosphorylated P70 S6 kinase,
phosphorylated mTOR, and phosphorylated 4EBP1 were
obtained from Abcam (Cambridge, MA). The antibody
against PSGR for immunohistochemistry was from Novus
Biologicals (Littleton, CO).
Immunohistochemistry
Tissue microarray sections were immunohistochemically
stained with PSGR antibody as previously described [11].
Briefly, TMA sections were de-paraffinized and rehydrated
through graded alcohols. Antigen retrieval was performed
by boiling in an EDTA buffer (pH 9.0) at 98 °C for 20 min.
Endogenous peroxidase activity was blocked with 3 %
hydrogen peroxide. The slides were incubated with anti-
body against PSGR (NLS6332, rabbit polyclonal, 1: 100) at
room temperature for one hour and were subsequently in-
cubated for 30 min with EnVision + System horseradish
peroxidase-labeled polymer conjugated with biotinylated
anti-rabbit secondary antibody and 3,3′-diaminobenzidine
substrate. All sections were counterstained with Mayer’s
hematoxylin. Normal prostate and testes were used as
positive and negative control for PSGR. Negative controls
were also established by the replacement of primary anti-
bodies with normal serum.
Evaluation of immunohistochemical staining
Membranous and cytoplasmic PSGR staining was ob-
served in the epithelial cell of normal prostate, PIN and
PCa (Fig. 1a). To more precisely represent the expression
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level of PSGR, the H-score system was employed in this
study. Two independent researchers (JZY and WQC) eval-
uated the stained slides as described previously [12]. The
staining intensity for each protein was scored as 0, no stain-
ing; 1+, weak; 2+, moderate; and 3+, strong staining. The
percentage of tumor cells that stained positive was also esti-
mated (0–100 %). A H score (range 0–300) was generated
by multiplying the staining intensity score and the per-
centage of positively stained tumor cells (H-Score = 3×
percentage of cells with strong staining + 2× percentage of
cells with moderate staining + 1× percentage of cells with
weak staining + 0× percentage of cells with no staining).
The Kappa value for inter-observer agreement between
the two researchers was 0.85.
Cell culture and invasion assay
LNCaP, PC3, and C4-2 human PCa cell lines were ob-
tained from the American Type Culture Collection
(ATCC). Cells were cultured in Dulbecco’s modified
Eagle’s medium, supplemented with 10 % of FBS and
antibiotics in 100 mm cell culture dishes or culture
plates. 12 h prior to experimentation, cells were cultured
in Dulbecco’s modified Eagle’s medium with 5 % char-
coal treated FBS and antibiotics.
To measure cell invasion, an insert with 8.0 μm pores
(Corning) was coated with matrigel (BD Biosciences) and
5 × 105 C4-2 cells were seeded. After 3 days with β- or
α-ionone treatment, the cells remaining in the upper
compartment of insert were removed by cotton swabs,
and those invaded through the matrix were stained with
0.1 % crystal violet and counted under a light micro-
scope at five individual fields per insert. Results were
presented as an average of triplicate experiments.
Cell proliferation and growth assay
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium
bromide) assay and anchorage-independent growth assay
were performed to measure cell proliferation following
previously published protocols [13]. Briefly, for MTT
assay, cells were seeded in 24-well plates. After 3 days cul-
ture, the medium was removed and the cells were washed
once with PBS. 300 μl of serum-free medium and 30 μl of
MTT reagent (5 mg/ml) were added, and incubated for
one and a half hours in a humidified 5 % CO2 incubator
at 37 °C. The absorbance was measured using a BIORAD
Microplate reader at wavelength of 570 and 620 nm. The
different absorbance values at 570 and 620 nm wavelength
represented the direct correlation with number of viable
cells per well. For anchorage-independent growth assay:
soft agar plates were prepared in six-well plates with a
bottom layer of 0.8 % Noble agar in serum-free DMEM
2 × 104 cells mixed with 0.8 % Noble agar in 10 % fetal calf
serum-supplemented DMEM were seeded as the top agar
layer onto the agar plates. Colonies were visualized after
Fig. 1 Expression of PSGR protein in normal prostate (N), prostatic intraepithelial neoplasia (PIN) and prostate cancer (PCa) by immunohistochemistry.
A Low (a-c) and high magnification (d-f) images of PSGR staining in N (a, d), PIN (b, e) and PCa (c, f); B Low (a and b) and high (c and d) magnification
images of PSGR in N and adjacent PIN (a, c), and PIN and adjacent PCa (b, d) (original magnification x 10 and x 20 for low and high respectively)
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six weeks culture by staining with 0.005 % crystal violet.
Two wells were prepared for each treatment and the
experiments were repeated twice.
Western blot
Cells were lysed in a 500 μl lysis buffer (PBS, 0.5 %
Triton X-100, 5 mM EDTA, and protease inhibitors) on
ice for 30 min. The lysate was collected and cleared by
centrifuging at 12,000 g for 20 min at 4 °C. Protein
concentration of supernatants was determined by the
Bradford’s method (Bio-Rad Laboratories protein assay,
Hercules, CA, USA). 10 μg of the sample was separated
by SDS-polyacrylamide gel electrophoresis and blotted
as previously described [14]. Specific antibodies against
AR, PSGR, Phosphorylated P70 S6 kinase, phosphory-
lated mTOR, and phosphorylated 4EBP1 were used for
western blots (1:1000).
Statistical analysis
Statistical analysis was performed using the Prism 5 stat-
istical package from GraphPad Software, Inc. (La Jolla,
CA). Data was analyzed and expressed as mean ± S.E.
Overall survival (OS) was defined as the time from the
date of diagnosis to the date of death or final clinical
follow-up. The Kaplan-Meier method was used to
estimate survival probabilities in patient subgroups. Sig-
nificant difference of PSGR expression among/between
groups was determined by one-way analysis of variance
or Student’s t-test. A p value less than 0.05 was consid-
ered statistically significant.
Results
PSGR protein expression is significantly increased in PIN,
but not in PCa
In our study, the distribution of PSGR in six types of
normal human tissues and paired normal prostate, PIN,
and PCa was tested with immunohistochemistry. Posi-
tive PSGR staining was located in the cytoplasm and cell
membrane of normal prostate luminal epithelial cells
(Fig. 1A), but not in normal liver, testes, colon, placenta
Fig. 2 Expression of PSGR protein in other normal tissues by immunohistochemistry. PSGR staining in normal liver (a), colon (b), testes (c), pancreas
(d), placenta (e) and thyroid (f) (original magnification x 20)
Table 1 Associations of PSGR expression with clinicopathological
characteristics of PCa
PSGR
Mean ± SE P
Age (years)
≤ 61 (n = 72) 130.90 ± 6.72 0.95
> 61 (n = 78) 131.40 ± 6.03
Tumor stage
T2a (n = 26) 146.60 ± 11.90 0.33
T2b (n = 39) 127.61 ± 8.06
T2c (n = 48) 124.21 ± 7.74
T3+ (n = 37) 132.80 ± 7.52
Lymphovascular invasion
Present (n = 66) 125.30 ± 6.51 0.19
Absent (n = 84) 136.72 ± 5.87
Extraprostatic extension
Present (n = 65) 135.10 ± 6.99 0.83
Absent (n = 85) 132.90 ± 6.67
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Fig. 3 Expression levels of PSGR assessed by H-Score. a Distribution of H-Score of PSGR in adjacent normal prostate (N), PIN and PCa. b Association of
PSGR protein expression with Gleason score. No statistically significant difference was observed between PCa and N. c Kaplan-Meier overall survival
curves of PSGR expression
Fig. 4 Activated PSGR by β-ionone inhibits C4-2 cell growth. a Western blot shows expression of PSGR protein in indicated PCa cell lines (n = 2).
b MTT assay shows the effect of β-ionone on cell proliferation with indicated doses. C4-2, PC3 and LNCaP cells were treated for 3 days (n = 6).
* indicated p < 0.05 compared to DMSO alone group. c Effect of α-ionone on C4-2, PC3 and LNCaP cell proliferation with indicated doses (n = 5).
Cells were treated for 3 days. d Anchorage-Independent Growth Assay to evaluate the inhibitory effect of β-ionone on C4-2 cell growth. The
image represents one of the three individual experiments. e Quantification data from anchorage-independent growth assay (n = 3)
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or thyroid tissues (Fig. 2). Positive PSGR staining was
also found in epithelial cells in PIN and PCa (Fig. 1A).
Since the staining of PSGR could be patchy and staining
intensity was variable in tissue samples (Fig. 1A), a
H-score method was used to evaluate PSGR immunohis-
tochemistry. A higher PSGR expression was found in PIN
(H-score, 176.4 ± 5.12), compared to that in normal
prostate (H-score, 132.6 ± 4.20, P < 0.001). Interestingly,
the protein expression of PSGR decreased in PCa
(H-score, 131.7 ± 4.37, P < 0.001) relative to PIN, which
was close to that in normal prostate (Fig. 3a). Images in
Fig. 1B clearly showed higher expression of PSGR in PIN
compared to adjacent normal prostate or PCa in the same
sections.
The associations of PSGR expression with
clinicopathological characteristics and patient overall
survival
In our cohort of 150 patients, the median age at the time
of PCa diagnosis was 61 years (range: 43 to 73 years). Sur-
vival information was available in 148 out of 150 patients.
Expression of PSGR was not correlated with patient’s age,
tumor stage, lymphovascular invasion or extraprostatic
extension (Table 1). A lower PSGR protein expression was
associated with higher Gleason pattern/score (Fig. 3b).
The median H-score of PSGR in PCa was 115. Using the
median score, the cohort was categorized into two groups,
high expression of PSGR (H-score ≥115) and low ex-
pression of PSGR (H-score < 115). Kaplan-Meier analysis
showed that low expression of PSGR was associated with
poor OS (Fig. 3c).
Activation of PSGR inhibits proliferation of C4-2 cells, but
promotes cancer cell invasion
We evaluated PSGR expression by Western Blot in sev-
eral PCa cell lines including LNCaP, PC3 and C4-2 cells.
The data indicated that C4-2 cells and LNCaP cells
expressed PSGR, whereas PC3 cells were PSGR negative
(Fig. 4a). PC3 cells were therefore adopted as a negative
control in the study. We observed retarded proliferation
of C4-2 cells after treatment with β-ionone, a PSGR
agonist, following MTT and anchorage-independent
growth assay (Fig. 4b, d and e). In contrast, PC3 cell
proliferation was not altered by β-ionone treatment
(Fig. 4b). In addition, we also tested the inhibitory effect
of β-ionone on LNCaP cell growth in our study as a
positive control. As previously reported [8], we found
β-ionone retarded LNCaP cell growth in the study
(Fig. 4b). To further identify the specific effect of β-
ionone on PSGR in C4-2 cells, α-ionone, a substance
structurally similar to β-ionone without the ability to acti-
vate PSGR [8], was employed as another negative control.
As expected, α-ionone treatment did not alter the prolifer-
ation of C4-2 cells (Fig. 4c). Subsequently, we tested if ac-
tivated PSGR affected cancer cell invasive ability. Our data
showed β-ionone, but not α-ionone, promoted C4-2 cell
invasion (Fig. 5a and b), which was consistent with re-
cently published data from LNCaP cells [10].
Phosphorylated p70 S6 kinase is decreased by
activated PSGR
A previous study with LNCaP cells revealed that PSGR
directly activated Src kinase [9]. Src kinase is an
Fig. 5 β-ionone reduced the invasive ability of C4-2 cells. a Representative images of invasive C4-2 cells stained with 0.1 % crystal violet (see detail
Methods). b Quantification data from invasion experiments (n = 4)
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important regulator for mTOR signaling in cancer [15].
Alterations in the mTOR pathway have been detected in
PCa tissues in multiple studies, suggesting that this path-
way plays an important role in the development and
progression of PCa [16]. Inhibition of mTOR signaling
has emerged as a potential therapeutic strategy for PCa
[17, 18]. Data from this study indicated that activated
PSGR retarded C4-2 cell growth and increased cell inva-
sive ability. To evaluate if activated PSGR altered the
mTOR signaling activity, we tested the activity of
mTOR, and potential mTOR downstream molecules
(p70 S6 kinase and 4EBP1) by Western Blot with specific
phosphorylated antibodies. The data demonstrated that
β-ionone stimulation did not alter mTOR and 4EBP1 ac-
tivities in C4-2 cells (PSGR+) or PC3 cells (PSGR-).
However, β-ionone treatment decreased p70 S6 kinase
activity in dose dependent manner in C4-2 cells, but not
in PC3 cells (Fig. 6a and b).
Discussion
In this study, we evaluated the expression of PSGR pro-
tein in a large cohort of PCa patients using paired adja-
cent normal prostate, PIN, and PCa tissues. Our data
not only confirmed PSGR specific expression in prostate
luminal cells, but also revealed its dynamic pattern
among normal prostate, PIN, and PCa. High expression
of PSGR was seen in PIN, but not in PCa. Interestingly,
low expression of PSGR protein in PCa was associated
with high Gleason score and poor overall survival. This
data suggested that PSGR may be a predictive marker
for early PCa diagnosis and poor prognosis. In addition,
our data from cell experiments indicated that PSGR
might contribute to PCa progression by altering PCa cell
growth and promoting cell invasion. P70 S6 kinase
might be one of the important downstream molecules to
mediate PSGR signaling. Notably, high grade PIN, a pre-
cursor of PCa, possesses the potential to develop to PCa.
Further studies will be needed to identify the role of
PSGR in the transformation of PIN to PCa.
Results from Quantitative-PCR and Northern blot
have indicated that PSGR mRNA is relatively specifically
expressed in prostate epithelial cells [2, 19, 20]. In the
current study, PSGR protein expression was seen in nor-
mal prostate but not in testes, liver, colon, placenta, and
thyroid tissues, providing more evidence for specific
PSGR expression in prostate. Moreover, compared to
non-cancerous controls, PSGR mRNA was significantly
increased in PIN lesions [3]. In accordance with these
findings, we showed highest PSGR protein expression in
PIN compared to normal prostate and PCa, further sug-
gesting that PSGR may play an important role in pros-
tate cancer initiation. Notably, PSGR mRNA transcripts
were shown to increase in PCa compared to that in non-
cancerous tissues in several reports [2, 3, 20]. However,
the data in this study showed a significant decrease of
PSGR protein level in PCa compared to that in PIN. The
differences of data may result from the following two
reasons: 1) Previous studies evaluated the mRNA level
of PSGR, whereas we studied PSGR protein expression.
Evidence have delineated that about 60 % of variation in
protein concentration was not able to be explained by
knowing mRNA abundance [21]. 2) Previous studies iso-
lated mRNA either from whole tissues or a small
amount of desired prostate epithelial cells by laser
micro-dissection [2, 3, 20]. It is possible that the tissues
used for RNA isolation might have PIN mixed with PCa.
A recent study has demonstrated no apparent correl-
ation between PSGR mRNA level and pathologic factors
such as clinical stage, patient age, recurrent status, and
serum PSA level before treatment [3]. The results from
this study also showed no correlation of PSGR protein
expression with patient age, clinical stage, lymphovas-
cular invasion, or extraprostatic extension. However the
Fig. 6 Phosphorylated status of mTOR, 4EBP1 and P70 S6 kinase.
a C4-2 and PC3 PCa cells were treated by β-ionone for 3 days. The
images of the blots represent one of the three individual experiments.
P-mTOR, P-4EBP1 and P-S6K indicate phosphorylated mTOR,
phosphorylated 4EBP1 and phosphorylated P70 S6 kinase, respectively.
b Integrated optical density of each band measured by NIH Image J
represents the expression of protein. Bar graphs show quantification of
the expression level of P-S6K protein compared with the expression
of GAPDH (Data are expressed as means ± SEM (n = 3). *p < 0.05
compared to DMSO group. **P < 0.05 compared to group treated with
100 μM β-ionone
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data showed low PSGR expression was associated with
high Gleason score, and poor OS. Our data suggested
that PSGR protein expression might serve as a predictor
for prognosis. Interestingly, detecting transcripts of PSGR
in post-prostate massage urine seems to increase sensitivity
and specificity of predicting PCa prognosis [7, 22]. Since
PSGR expression is significantly increased in PIN and
then decreased in PCa, we postulate that measuring PSGR
protein expression dynamic change in post-prostate mas-
sage urine may be a reliable way to predict early PCa
development.
There is limited information about PSGR signaling
biological and pathological significance in prostate and
PCa. Our data indicated that low PSGR protein level in
PCa correlated with poor prognosis. Recent reports have
demonstrated that activated PSGR with its selective
agonist, β-ionone, inhibits LNCaP cell proliferation and
increases its invasion ability [8, 10]. To explore the po-
tential role of PSGR in tumor progression, we tested the
effect of activated PSGR in C4-2 cells on cell growth and
invasion. In agreement with the published results from
LNCaP cells, β-ionone retarded C4-2 cell growth and in-
creased cell invasion ability. This data further suggested
that PSGR signaling might play an important role in
PCa progression by disrupting cancer cell growth and
promoting cell invasion. Manipulating PSGR activity
might be a potential approach to treat PCa.
Several lines of evidence have suggested that MAPK,
Src, and PI3K might be the downstream molecules for
PSGR signaling [8–10]. PI3K and Src are important
regulators for mTOR signaling. P70 S6 kinase and
4EBP1 are important downstream molecules of mTOR
signaling transduction [23]. Studies have indicated that
phosphorylation of p70 S6 kinase and 4EBP1 by mTOR
plays an essential role in tumor growth and metastasis
[24–26]. We hypothesized that activated PSGR might
alter mTOR signaling activity. However, our data
showed that activation of PSGR decreased p70 S6 kinase
activity but did not change phosphorylated mTOR or
4EBP1 status in C4-2 cells. This data suggested that
PSGR might regulate p70 S6 kinase activity in a man-
ner independent of mTOR. Actually, G protein
coupled receptor participating in regulating p70 S6
kinase activity in tumor cells has been reported in
previous studies [27, 28].
Conclusions
In summary, we demonstrated that PSGR protein was
specifically expressed in normal prostate. Its expression
was increased in PIN. Low expression of PSGR protein
in PCa correlated with high Gleason score and poor
overall survival. PSGR is not only a potential marker for
predicting PCa initiation and prognosis, but also a po-
tential target for PCa treatment.
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